stoxline Quote Chart Rank Option Currency Glossary
  
Akari Therapeutics, Plc (AKTX)
3.3  0.16 (5.1%)    06-12 16:00
Open: 3.21
High: 3.3
Volume: 44,616
  
Pre. Close: 3.14
Low: 2.6
Market Cap: 30(M)
Technical analysis
2024-06-12 4:20:15 PM
Short term     
Mid term     
Targets 6-month :  3.85 1-year :  4.5
Resists First :  3.29 Second :  3.85
Pivot price 2.11
Supports First :  2.07 Second :  1.32
MAs MA(5) :  2.63 MA(20) :  1.96
MA(100) :  1.92 MA(250) :  2.86
MACD MACD :  0.3 Signal :  0.1
%K %D K(14,3) :  88.6 D(3) :  86.4
RSI RSI(14): 83.2
52-week High :  5.5 Low :  1.07
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ AKTX ] has closed above the upper band by 5.0%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 210.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.3 - 3.32 3.32 - 3.33
Low: 2.57 - 2.59 2.59 - 2.6
Close: 3.08 - 3.11 3.11 - 3.13
Company Description

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Headline News

Wed, 12 Jun 2024
Akari Therapeutics (NASDAQ:AKTX) Now Covered by Analysts at StockNews.com - Defense World

Tue, 11 Jun 2024
Akari Therapeutics (NASDAQ:AKTX) Stock Price Crosses Above 50-Day Moving Average of $1.54 - Defense World

Wed, 05 Jun 2024
Akari Therapeutics announces interm CEO employment contract - Seeking Alpha

Wed, 05 Jun 2024
Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders - Yahoo Finance

Tue, 04 Jun 2024
Akari Therapeutics secures $7.6 million in private financing By Investing.com - Investing.com

Tue, 04 Jun 2024
Akari Therapeutics raises $7.6M in upsized financing round (NASDAQ:AKTX) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 12 (M)
Shares Float 3,200 (M)
Held by Insiders 11 (%)
Held by Institutions 107 (%)
Shares Short 1 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -3.15
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.53
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -211 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.56
Qtrly Earnings Growth 0 %
Operating Cash Flow -16 (M)
Levered Free Cash Flow -10 (M)
Stock Valuations
PE Ratio -1
PEG Ratio 0
Price to Book value -5.87
Price to Sales 0
Price to Cash Flow -2.35
Stock Dividends
Dividend 0
Forward Dividend 12630
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android